



CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)

(in millions)	2021				2022				2023
	Mar 31	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30	Sep 30	Dec 31	Mar 31
Assets									
Cash, cash equivalents and marketable securities	\$ 6,245	\$ 7,361	\$ 6,837	\$ 7,829	\$ 6,752	\$ 7,000	\$ 6,942	\$ 7,630	\$ 7,200
Accounts receivable, net	3,925	4,149	4,566	4,493	3,787	4,118	4,354	4,777	4,162
Inventories	2,996	2,988	2,797	2,734	2,675	2,587	2,602	2,820	3,010
Property, plant and equipment, net	4,990	4,996	5,037	5,121	5,253	5,299	5,349	5,475	5,479
Intangible assets, net	34,781	34,341	33,900	33,455	30,331	29,885	29,440	28,894	28,348
Goodwill	8,334	8,334	8,332	8,332	8,314	8,314	8,314	8,314	8,314
Other assets	6,221	5,815	5,629	5,988	5,968	5,667	5,556	5,261	5,364
Total assets	\$ 67,492	\$ 67,984	\$ 67,098	\$ 67,952	\$ 63,080	\$ 62,870	\$ 62,557	\$ 63,171	\$ 61,876
Liabilities and Stockholders' Equity									
Current liabilities	\$ 9,705	\$ 10,214	\$ 10,245	\$ 11,610	\$ 8,558	\$ 9,220	\$ 10,423	\$ 11,237	\$ 10,528
Long-term liabilities	38,823	38,060	35,382	35,278	34,607	33,435	31,077	30,725	30,409
Stockholders' equity	18,964	19,710	21,471	21,064	19,915	20,215	21,057	21,209	20,939
Total liabilities and stockholders' equity	\$ 67,492	\$ 67,984	\$ 67,098	\$ 67,952	\$ 63,080	\$ 62,870	\$ 62,557	\$ 63,171	\$ 61,876

Certain amounts and percentages may not sum or recalculate due to rounding.



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP
(unaudited)

(in millions, except percentages and per share amounts)	2021					2022					2023	
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1	
Revenues:												
Product sales	\$ 6,340	\$ 6,152	\$ 7,356	\$ 7,160	\$ 27,008	\$ 6,534	\$ 6,138	\$ 6,978	\$ 7,333	\$ 26,982	\$ 6,306	
Royalty, contract and other revenues	83	65	65	84	297	56	122	64	56	299	46	
Total revenues	6,423	6,217	7,421	7,244	27,305	6,590	6,260	7,042	7,389	27,281	6,352	
Costs and expenses:												
Cost of goods sold	1,361	1,390	1,223	2,627	6,601	1,424	1,442	1,395	1,396	5,657	1,401	
Research and development expenses	1,050	1,092	1,101	1,358	4,601	1,178	1,102	1,149	1,548	4,977	1,447	
Acquired in-process research and development expenses	67	138	65	669	939	8	330	448	158	944	481	
In-process research and development impairment	—	—	—	—	—	2,700	—	—	—	2,700	—	
Selling, general and administrative expenses	1,055	1,351	1,190	1,650	5,246	1,083	1,357	1,213	2,020	5,673	1,319	
Total costs and expenses	3,533	3,971	3,579	6,304	17,387	6,393	4,231	4,205	5,122	19,951	4,647	
Operating income	2,890	2,246	3,842	940	9,918	197	2,029	2,837	2,267	7,330	1,705	
Interest expense	(257)	(256)	(250)	(238)	(1,001)	(238)	(242)	(229)	(227)	(935)	(230)	
Other income (expense), net	(369)	(173)	(154)	57	(639)	(111)	(284)	(176)	(9)	(581)	(174)	
Income (loss) before income taxes	2,264	1,817	3,438	759	8,278	(152)	1,503	2,432	2,031	5,814	1,300	
Income tax (expense) benefit	(542)	(300)	(852)	(383)	(2,077)	164	(368)	(646)	(398)	(1,248)	(316)	
Net income	1,722	1,517	2,586	376	6,201	12	1,135	1,786	1,633	4,566	985	
Net loss attributable to noncontrolling interest	7	5	6	6	24	7	9	3	7	26	26	
Net income attributable to Gilead	\$ 1,729	\$ 1,522	\$ 2,592	\$ 382	\$ 6,225	\$ 19	\$ 1,144	\$ 1,789	\$ 1,640	\$ 4,592	\$ 1,010	
Basic earnings per share attributable to Gilead	\$ 1.38	\$ 1.21	\$ 2.06	\$ 0.30	\$ 4.96	\$ 0.02	\$ 0.91	\$ 1.43	\$ 1.31	\$ 3.66	\$ 0.81	
Shares used in basic earnings per share attributable to Gilead calculation	1,256	1,255	1,256	1,256	1,256	1,255	1,256	1,255	1,252	1,255	1,248	
Diluted earnings per share attributable to Gilead	\$ 1.37	\$ 1.21	\$ 2.05	\$ 0.30	\$ 4.93	\$ 0.02	\$ 0.91	\$ 1.42	\$ 1.30	\$ 3.64	\$ 0.80	
Shares used in diluted earnings per share attributable to Gilead calculation	1,262	1,260	1,262	1,262	1,262	1,262	1,260	1,261	1,264	1,262	1,261	
Cash dividends declared per share	\$ 0.71	\$ 0.71	\$ 0.71	\$ 0.71	\$ 2.84	\$ 0.73	\$ 0.73	\$ 0.73	\$ 0.73	\$ 2.92	\$ 0.75	
Product gross margin	78.5 %	77.4 %	83.4 %	63.3 %	75.6 %	78.2 %	76.5 %	80.0 %	81.0 %	79.0 %	77.8 %	
Research and development expenses as a % of revenues	16.3 %	17.6 %	14.8 %	18.7 %	16.9 %	17.9 %	17.6 %	16.3 %	20.9 %	18.2 %	22.8 %	
Selling, general and administrative expenses as a % of revenues	16.4 %	21.7 %	16.0 %	22.8 %	19.2 %	16.4 %	21.7 %	17.2 %	27.3 %	20.8 %	20.8 %	
Operating margin	45.0 %	36.1 %	51.8 %	13.0 %	36.3 %	3.0 %	32.4 %	40.3 %	30.7 %	26.9 %	26.8 %	
Effective tax rate	23.9 %	16.5 %	24.8 %	50.5 %	25.1 %	107.9 %	24.5 %	26.6 %	19.6 %	21.5 %	24.3 %	

Certain amounts and percentages may not sum or recalculate due to rounding.



SELECTED CASH FLOW INFORMATION
(unaudited)

(in millions)	2021					2022					2023
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1
Net cash provided by operating activities	\$ 2,610	\$ 2,316	\$ 3,253	\$ 3,205	\$ 11,384	\$ 1,840	\$ 1,802	\$ 2,863	\$ 2,566	\$ 9,072	\$ 1,744
Net cash used in investing activities	(2,042)	(577)	(234)	(278)	(3,131)	(1,070)	(308)	(713)	(374)	(2,466)	(826)
Net cash used in financing activities	(2,477)	(931)	(3,527)	(1,942)	(8,877)	(1,794)	(1,003)	(2,118)	(1,554)	(6,469)	(1,406)
Effect of exchange rate changes on cash and cash equivalents	(23)	20	(23)	(9)	(35)	(18)	(48)	(72)	75	(63)	13
Net change in cash and cash equivalents	(1,932)	828	(531)	976	(659)	(1,042)	443	(40)	713	74	(476)
Cash and cash equivalents, beginning of period	5,997	4,065	4,893	4,362	5,997	5,338	4,296	4,739	4,699	5,338	5,412
Cash and cash equivalents, end of period	<u>\$ 4,065</u>	<u>\$ 4,893</u>	<u>\$ 4,362</u>	<u>\$ 5,338</u>	<u>\$ 5,338</u>	<u>\$ 4,296</u>	<u>\$ 4,739</u>	<u>\$ 4,699</u>	<u>\$ 5,412</u>	<u>\$ 5,412</u>	<u>\$ 4,936</u>

(in millions)	2020					2021					2023
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1
Net cash provided by operating activities	\$ 2,610	\$ 2,316	\$ 3,253	\$ 3,205	\$ 11,384	\$ 1,840	\$ 1,802	\$ 2,863	\$ 2,566	\$ 9,072	\$ 1,744
Capital expenditures	(165)	(119)	(139)	(156)	(579)	(247)	(143)	(157)	(181)	(728)	(109)
Free cash flow ⁽¹⁾	<u>\$ 2,445</u>	<u>\$ 2,197</u>	<u>\$ 3,114</u>	<u>\$ 3,049</u>	<u>\$ 10,805</u>	<u>\$ 1,593</u>	<u>\$ 1,659</u>	<u>\$ 2,706</u>	<u>\$ 2,386</u>	<u>\$ 8,344</u>	<u>\$ 1,635</u>

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on April 27, 2023 on Form 8-K, which is available on <http://investors.gilead.com>.



NON-GAAP FINANCIAL INFORMATION⁽¹⁾
(unaudited)

(in millions, except percentages and per share amounts)	2021					2022					2023	
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1	
Non-GAAP:												
Cost of goods sold	\$ 855	\$ 836	\$ 736	\$ 2,111	\$ 4,538	\$ 825	\$ 886	\$ 923	\$ 968	\$ 3,602	\$ 871	
Research and development expenses	\$ 1,044	\$ 1,042	\$ 1,063	\$ 1,315	\$ 4,464	\$ 1,150	\$ 1,102	\$ 1,173	\$ 1,544	\$ 4,968	\$ 1,439	
Acquired in-process research and development expenses	\$ 67	\$ 138	\$ 65	\$ 669	\$ 939	\$ 8	\$ 330	\$ 448	\$ 158	\$ 944	\$ 481	
Selling, general and administrative expenses	\$ 1,033	\$ 1,121	\$ 1,178	\$ 1,642	\$ 4,974	\$ 1,083	\$ 1,272	\$ 1,212	\$ 2,020	\$ 5,587	\$ 1,318	
Other income (expense), net	\$ (18)	\$ 1	\$ (12)	\$ —	\$ (29)	\$ (15)	\$ 20	\$ 20	\$ 52	\$ 77	\$ 82	
Diluted EPS	\$ 2.04	\$ 1.81	\$ 2.65	\$ 0.69	\$ 7.18	\$ 2.12	\$ 1.58	\$ 1.90	\$ 1.67	\$ 7.26	\$ 1.37	
Product gross margin	86.5 %	86.4 %	90.0 %	70.5 %	83.2 %	87.4 %	85.6 %	86.8 %	86.8 %	86.6 %	86.2 %	
Research and development expenses as a % of revenues	16.3 %	16.8 %	14.3 %	18.2 %	16.3 %	17.5 %	17.6 %	16.7 %	20.9 %	18.2 %	22.6 %	
Selling, general and administrative expenses as a % of revenues	16.1 %	18.0 %	15.9 %	22.7 %	18.2 %	16.4 %	20.3 %	17.2 %	27.3 %	20.5 %	20.7 %	
Operating margin	53.3 %	49.5 %	59.0 %	20.8 %	45.4 %	53.5 %	42.7 %	46.7 %	36.5 %	44.6 %	35.3 %	
Effective tax rate	18.4 %	19.5 %	18.9 %	32.2 %	20.4 %	18.4 %	19.3 %	22.4 %	16.8 %	19.3 %	18.9 %	

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on April 27, 2023 on Form 8-K, which is available on <http://investors.gilead.com>. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 5 - 6.



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)

(in millions, except percentages and per share amounts)	2021					2022					2023	
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1	
Cost of goods sold reconciliation:												
GAAP cost of goods sold	\$ 1,361	\$ 1,390	\$ 1,223	\$ 2,627	\$ 6,601	\$ 1,424	\$ 1,442	\$ 1,395	\$ 1,396	\$ 5,657	\$ 1,401	
Acquisition-related – amortization ⁽¹⁾	(506)	(554)	(487)	(516)	(2,063)	(557)	(556)	(472)	(428)	(2,013)	(530)	
Other ⁽²⁾	—	—	—	—	—	(42)	—	—	—	(42)	—	
Non-GAAP cost of goods sold	\$ 855	\$ 836	\$ 736	\$ 2,111	\$ 4,538	\$ 825	\$ 886	\$ 923	\$ 968	\$ 3,602	\$ 871	
Product gross margin reconciliation:												
GAAP product gross margin	78.5 %	77.4 %	83.4 %	63.3 %	75.6 %	78.2 %	76.5 %	80.0 %	81.0 %	79.0 %	77.8 %	
Acquisition-related – amortization ⁽¹⁾	8.0 %	9.0 %	6.6 %	7.2 %	7.6 %	8.5 %	9.1 %	6.8 %	5.8 %	7.5 %	8.4 %	
Other ⁽²⁾	— %	— %	— %	— %	— %	0.6 %	— %	— %	— %	0.2 %	— %	
Non-GAAP product gross margin	86.5 %	86.4 %	90.0 %	70.5 %	83.2 %	87.4 %	85.6 %	86.8 %	86.8 %	86.6 %	86.2 %	
Research and development expenses reconciliation:												
GAAP research and development expenses	\$ 1,050	\$ 1,092	\$ 1,101	\$ 1,358	\$ 4,601	\$ 1,178	\$ 1,102	\$ 1,149	\$ 1,548	\$ 4,977	\$ 1,447	
Acquisition-related – amortization ⁽¹⁾	—	—	(67)	(42)	(109)	—	—	—	—	—	—	
Acquisition-related – other costs ⁽³⁾	(6)	(6)	(2)	(1)	(14)	(10)	—	24	(1)	13	(8)	
Other ⁽²⁾	—	(44)	31	(1)	(14)	(18)	—	—	(4)	(22)	—	
Non-GAAP research and development expenses	\$ 1,044	\$ 1,042	\$ 1,063	\$ 1,315	\$ 4,464	\$ 1,150	\$ 1,102	\$ 1,173	\$ 1,544	\$ 4,968	\$ 1,439	
IPR&D impairment reconciliation:												
GAAP IPR&D impairment	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 2,700	\$ —	\$ —	\$ —	\$ 2,700	\$ —	
IPR&D impairment	—	—	—	—	—	(2,700)	—	—	—	(2,700)	—	
Non-GAAP IPR&D impairment	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	
Selling, general and administrative expenses reconciliation:												
GAAP selling, general and administrative expenses	\$ 1,055	\$ 1,351	\$ 1,190	\$ 1,650	\$ 5,246	\$ 1,083	\$ 1,357	\$ 1,213	\$ 2,020	\$ 5,673	\$ 1,319	
Acquisition-related – other costs ⁽³⁾	(22)	(10)	(10)	(3)	(45)	—	—	(2)	(1)	(3)	(1)	
Other ⁽²⁾	—	(220)	(2)	(5)	(227)	—	(85)	1	1	(83)	—	
Non-GAAP selling, general and administrative expenses	\$ 1,033	\$ 1,121	\$ 1,178	\$ 1,642	\$ 4,974	\$ 1,083	\$ 1,272	\$ 1,212	\$ 2,020	\$ 5,587	\$ 1,318	
Operating income reconciliation:												
GAAP operating income	\$ 2,890	\$ 2,246	\$ 3,842	\$ 940	\$ 9,918	\$ 197	\$ 2,029	\$ 2,837	\$ 2,267	\$ 7,330	\$ 1,705	
Acquisition-related – amortization ⁽¹⁾	506	554	554	558	2,172	557	556	472	428	2,013	530	
Acquisition-related – other costs ⁽³⁾	28	16	12	3	59	10	—	(22)	2	(10)	9	
IPR&D impairment	—	—	—	—	—	2,700	—	—	—	2,700	—	
Other ⁽²⁾	—	264	(29)	6	241	60	85	(1)	2	147	—	
Non-GAAP operating income	\$ 3,424	\$ 3,080	\$ 4,379	\$ 1,507	\$ 12,390	\$ 3,524	\$ 2,670	\$ 3,286	\$ 2,699	\$ 12,180	\$ 2,243	
Operating margin reconciliation:												
GAAP operating margin	45.0 %	36.1 %	51.8 %	13.0 %	36.3 %	3.0 %	32.4 %	40.3 %	30.7 %	26.9 %	26.8 %	
Acquisition-related – amortization ⁽¹⁾	7.9 %	8.9 %	7.5 %	7.7 %	8.0 %	8.5 %	8.9 %	6.7 %	5.8 %	7.4 %	8.3 %	
Acquisition-related – other costs ⁽³⁾	0.4 %	0.3 %	0.2 %	0.1 %	0.2 %	0.2 %	— %	(0.3)%	— %	— %	0.1 %	
IPR&D impairment	— %	— %	— %	— %	— %	41.0 %	— %	— %	— %	9.9 %	— %	
Other ⁽²⁾	— %	4.2 %	(0.4)%	— %	0.9 %	0.9 %	1.4 %	— %	— %	0.5 %	— %	
Non-GAAP operating margin	53.3 %	49.5 %	59.0 %	20.8 %	45.4 %	53.5 %	42.7 %	46.7 %	36.5 %	44.6 %	35.3 %	
Other income (expense), net reconciliation:												
GAAP other income (expense), net	\$ (369)	\$ (173)	\$ (154)	\$ 57	\$ (639)	\$ (111)	\$ (284)	\$ (176)	\$ (9)	\$ (581)	\$ (174)	
Loss (gain) from equity securities, net	351	174	142	(57)	610	96	303	197	61	657	256	
Non-GAAP other income (expense), net	\$ (18)	\$ 1	\$ (12)	\$ —	\$ (29)	\$ (15)	\$ 20	\$ 20	\$ 52	\$ 77	\$ 82	



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)

(in millions, except per share amounts)	2021					2022					2023
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1
Effective tax rate reconciliation:											
GAAP effective tax rate	23.9 %	16.5 %	24.8 %	50.5 %	25.1 %	107.9 %	24.5 %	26.6 %	19.6 %	21.5 %	24.3 %
Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments ⁽⁴⁾	(5.6)%	3.0 %	(5.9)%	(18.3)%	(4.7)%	(89.5)%	(5.2)%	(4.1)%	(2.8)%	(2.1)%	(5.4)%
Non-GAAP effective tax rate	<u>18.4 %</u>	<u>19.5 %</u>	<u>18.9 %</u>	<u>32.2 %</u>	<u>20.4 %</u>	<u>18.4 %</u>	<u>19.3 %</u>	<u>22.4 %</u>	<u>16.8 %</u>	<u>19.3 %</u>	<u>18.9 %</u>
Net income attributable to Gilead reconciliation:											
GAAP net income attributable to Gilead	\$ 1,729	\$ 1,522	\$ 2,592	\$ 382	\$ 6,225	\$ 19	\$ 1,144	\$ 1,789	\$ 1,640	\$ 4,592	\$ 1,010
Acquisition-related – amortization ⁽¹⁾	409	446	446	449	1,750	443	442	379	346	1,610	422
Acquisition-related – other costs ⁽³⁾	22	15	9	—	46	10	—	(23)	1	(12)	6
IPR&D impairment	—	—	—	—	—	2,057	—	—	—	2,057	—
Other ⁽²⁾	—	166	(23)	3	146	45	59	—	2	106	—
Loss (gain) from equity securities, net	364	169	154	(56)	631	64	308	198	60	630	257
Discrete and related tax charges ⁽⁴⁾	54	(40)	165	88	267	38	31	49	57	175	29
Non-GAAP net income attributable to Gilead	<u>\$ 2,578</u>	<u>\$ 2,278</u>	<u>\$ 3,343</u>	<u>\$ 866</u>	<u>\$ 9,065</u>	<u>\$ 2,676</u>	<u>\$ 1,985</u>	<u>\$ 2,391</u>	<u>\$ 2,106</u>	<u>\$ 9,158</u>	<u>\$ 1,725</u>
Diluted earnings per share reconciliation:											
GAAP diluted earnings per share	\$ 1.37	\$ 1.21	\$ 2.05	\$ 0.30	\$ 4.93	\$ 0.02	\$ 0.91	\$ 1.42	\$ 1.30	\$ 3.64	\$ 0.80
Acquisition-related – amortization ⁽¹⁾	0.32	0.35	0.35	0.36	1.39	0.35	0.35	0.30	0.27	1.28	0.33
Acquisition-related – other costs ⁽³⁾	0.02	0.01	0.01	—	0.04	0.01	—	(0.02)	—	(0.01)	0.01
IPR&D impairment	—	—	—	—	—	1.63	—	—	—	1.63	—
Other ⁽²⁾	—	0.13	(0.01)	—	0.11	0.04	0.05	—	—	0.08	—
Loss (gain) from equity securities, net	0.29	0.13	0.12	(0.04)	0.50	0.05	0.24	0.16	0.05	0.50	0.20
Discrete and related tax charges ⁽⁴⁾	0.04	(0.03)	0.13	0.07	0.21	0.03	0.02	0.04	0.05	0.14	0.02
Non-GAAP diluted earnings per share	<u>\$ 2.04</u>	<u>\$ 1.81</u>	<u>\$ 2.65</u>	<u>\$ 0.69</u>	<u>\$ 7.18</u>	<u>\$ 2.12</u>	<u>\$ 1.58</u>	<u>\$ 1.90</u>	<u>\$ 1.67</u>	<u>\$ 7.26</u>	<u>\$ 1.37</u>
Non-GAAP adjustment summary:											
Cost of goods sold adjustments	\$ 506	\$ 554	\$ 487	\$ 516	\$ 2,063	\$ 599	\$ 556	\$ 472	\$ 428	\$ 2,055	\$ 530
Research and development expenses adjustments	6	50	38	43	137	28	—	(24)	4	9	8
IPR&D impairment adjustments	—	—	—	—	—	2,700	—	—	—	2,700	—
Selling, general and administrative expenses adjustments	22	230	12	8	272	—	85	1	—	86	1
Total non-GAAP adjustments to costs and expenses	534	834	537	567	2,472	3,327	641	450	432	4,850	539
Other income (expense), net, adjustments	351	174	142	(57)	610	96	303	197	61	657	256
Total non-GAAP adjustments before income taxes	885	1,008	679	510	3,082	3,423	945	646	493	5,507	795
Income tax effect of non-GAAP adjustments above	(90)	(212)	(93)	(114)	(509)	(803)	(135)	(93)	(84)	(1,116)	(109)
Discrete and related tax charges ⁽⁴⁾	54	(40)	165	88	267	38	31	49	57	175	29
Total non-GAAP adjustments after tax	<u>\$ 849</u>	<u>\$ 756</u>	<u>\$ 751</u>	<u>\$ 484</u>	<u>\$ 2,840</u>	<u>\$ 2,657</u>	<u>\$ 841</u>	<u>\$ 602</u>	<u>\$ 466</u>	<u>\$ 4,566</u>	<u>\$ 715</u>

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Relates to amortization of acquired intangibles and inventory step-up charges

⁽²⁾ Primarily includes (i) various restructuring expenses and (ii) expenses related to donations of equity securities to the Gilead Foundation, a California nonprofit organization.

⁽³⁾ Primarily includes employee-related expenses, contingent consideration fair value adjustments and other expenses associated with Gilead's acquisitions of Forty Seven, Inc., Immunomedics, Inc., MYR GmbH, MiroBio, Ltd., and Tmunity Therapeutics, Inc.

⁽⁴⁾ Includes discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.



**TOTAL REVENUE SUMMARY
(unaudited)**

(in millions)	2021					2022					2023	
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1	
Product sales ⁽¹⁾ :												
HIV	\$ 3,650	\$ 3,938	\$ 4,189	\$ 4,538	\$ 16,315	\$ 3,707	\$ 4,228	\$ 4,487	\$ 4,772	\$ 17,194	\$ 4,190	
Oncology	263	308	323	357	1,251	420	527	578	614	2,139	670	
Liver Disease	730	786	676	658	2,850	635	682	788	694	2,798	675	
Other	241	291	245	250	1,027	236	256	200	252	946	199	
Total product sales excluding Veklury	4,884	5,323	5,433	5,803	21,443	4,998	5,693	6,053	6,333	23,077	5,733	
Veklury	1,456	829	1,923	1,357	5,565	1,535	445	925	1,000	3,905	573	
Total product sales	6,340	6,152	7,356	7,160	27,008	6,534	6,138	6,978	7,333	26,982	6,306	
Royalty, contract and other revenues	83	65	65	84	297	56	122	64	56	299	46	
Total revenues	\$ 6,423	\$ 6,217	\$ 7,421	\$ 7,244	\$ 27,305	\$ 6,590	\$ 6,260	\$ 7,042	\$ 7,389	\$ 27,281	\$ 6,352	

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ See Product Sales Summary on pages 8-10 for more details.



PRODUCT SALES SUMMARY
(unaudited)

(in millions)	2021					2022					2023	
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1	
HIV												
Biktarvy – U.S.	\$ 1,465	\$ 1,586	\$ 1,875	\$ 2,123	\$ 7,049	\$ 1,706	\$ 2,095	\$ 2,286	\$ 2,423	\$ 8,510	\$ 2,161	
Biktarvy – Europe	216	237	254	262	969	261	268	278	295	1,103	304	
Biktarvy – Other Intl	143	171	147	145	606	184	193	201	200	777	212	
	1,824	1,994	2,276	2,530	8,624	2,151	2,556	2,766	2,918	10,390	2,677	
Complera/Eviplera – U.S.	25	20	28	29	102	17	20	20	17	74	14	
Complera/Eviplera – Europe	34	39	31	38	142	24	31	21	37	113	22	
Complera/Eviplera – Other Intl	4	3	5	2	14	4	3	3	3	13	3	
	63	62	64	69	258	44	54	43	58	200	39	
Descovy – U.S.	282	357	355	403	1,397	311	397	444	479	1,631	395	
Descovy – Europe	42	44	42	36	164	32	32	28	26	118	25	
Descovy – Other Intl	35	34	36	34	139	31	32	28	31	123	29	
	359	435	433	473	1,700	374	460	500	537	1,872	449	
Genvoya – U.S.	506	551	576	634	2,267	457	482	502	543	1,983	417	
Genvoya – Europe	106	100	100	85	391	77	72	71	64	284	55	
Genvoya – Other Intl	61	55	68	37	221	48	29	27	33	136	29	
	673	706	744	756	2,879	582	582	600	640	2,404	501	
Odefsey – U.S.	240	258	275	303	1,076	232	255	276	295	1,058	230	
Odefsey – Europe	113	111	112	104	440	96	97	86	85	364	76	
Odefsey – Other Intl	14	13	12	13	52	11	12	12	11	47	11	
	367	382	399	420	1,568	339	364	374	392	1,469	317	
Stribild – U.S.	31	35	28	38	132	22	24	22	20	88	20	
Stribild – Europe	11	11	11	10	43	8	8	7	7	29	6	
Stribild – Other Intl	4	5	3	2	14	3	2	3	3	10	2	
	46	51	42	50	189	32	33	32	29	127	28	
Truvada – U.S.	119	94	55	46	314	28	24	24	37	113	23	
Truvada – Europe	7	6	5	4	22	4	5	3	3	15	3	
Truvada – Other Intl	9	8	7	11	35	6	5	2	5	18	5	
	135	108	67	61	371	38	34	30	45	147	32	
Revenue share – Symtuza ⁽¹⁾ – U.S.	89	86	86	94	355	86	80	85	97	348	98	
Revenue share – Symtuza ⁽¹⁾ – Europe	44	40	41	40	165	44	42	40	42	168	36	
Revenue share – Symtuza ⁽¹⁾ – Other Intl	2	3	3	3	11	3	4	4	3	14	4	
	135	129	130	137	531	132	126	130	142	530	138	
Other HIV ⁽²⁾ – U.S.	29	57	24	26	136	5	5	1	4	15	4	
Other HIV ⁽²⁾ – Europe	5	8	6	11	30	4	9	6	5	24	1	
Other HIV ⁽²⁾ – Other Intl	14	6	4	5	29	5	4	5	3	17	3	
	48	71	34	42	195	14	18	12	12	57	9	
Total HIV – U.S.	2,786	3,044	3,302	3,696	12,828	2,862	3,383	3,661	3,914	13,820	3,364	
Total HIV – Europe	578	596	602	590	2,366	550	562	541	566	2,219	528	
Total HIV – Other Intl	286	298	285	252	1,121	295	282	285	293	1,155	298	
	3,650	3,938	4,189	4,538	16,315	3,707	4,228	4,487	4,772	17,194	4,190	

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Represents Gilead's revenue from cobicistat ("C"), emtricitabine ("FTC") and tenofovir alafenamide ("TAF") in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

⁽²⁾ Includes Atripla, Emtriva, Sunlenca and Tybost.



PRODUCT SALES SUMMARY (continued)
(unaudited)

(in millions)	2021					2022					2023	
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1	
Oncology												
Cell Therapy												
Tecartus – U.S.	27	32	35	42	136	47	53	60	61	221	59	
Tecartus – Europe	4	9	12	15	40	15	20	20	19	75	27	
Tecartus – Other Intl	—	—	—	—	—	1	—	1	1	3	3	
	31	41	47	57	176	63	73	81	82	299	89	
Yescarta – U.S.	92	108	100	106	406	125	193	210	219	747	210	
Yescarta – Europe	61	61	66	65	253	77	85	91	103	355	121	
Yescarta – Other Intl	7	9	9	11	36	9	17	16	15	57	28	
	160	178	175	182	695	211	295	317	337	1,160	359	
Total Cell Therapy – U.S.	119	140	135	148	542	172	246	270	281	968	269	
Total Cell Therapy – Europe	65	70	78	80	293	92	105	111	122	430	148	
Total Cell Therapy – Other Intl	7	9	9	11	36	10	17	17	17	60	31	
	191	219	222	239	871	274	368	398	419	1,459	448	
Trodelvy												
Trodelvy – US	72	89	100	109	370	119	120	139	146	525	162	
Trodelvy – Europe	—	—	1	9	10	25	35	38	44	143	54	
Trodelvy – Other Intl	—	—	—	—	—	2	3	3	4	12	6	
	72	89	101	118	380	146	159	180	195	680	222	
Total Oncology – U.S.	191	229	235	257	912	292	366	409	427	1,494	431	
Total Oncology – Europe	65	70	79	89	303	117	140	149	166	573	202	
Total Oncology – Other Intl	7	9	9	11	36	11	20	20	21	73	37	
	263	308	323	357	1,251	420	527	578	614	2,139	670	
Liver Disease												
HCV												
Ledipasvir/Sofosbuvir ⁽³⁾ – U.S.	19	30	14	21	84	13	6	8	19	46	3	
Ledipasvir/Sofosbuvir ⁽³⁾ – Europe	16	3	5	7	31	4	4	5	4	17	7	
Ledipasvir/Sofosbuvir ⁽³⁾ – Other Intl	21	29	26	21	97	18	13	12	8	51	5	
	56	62	45	49	212	35	23	25	31	115	15	
Sofosbuvir/Velpatasvir ⁽⁴⁾ – U.S.	214	262	173	166	815	162	227	241	214	844	204	
Sofosbuvir/Velpatasvir ⁽⁴⁾ – Europe	75	82	77	82	316	83	75	131	67	355	90	
Sofosbuvir/Velpatasvir ⁽⁴⁾ – Other Intl	92	98	82	59	331	85	74	84	87	331	90	
	381	442	332	307	1,462	330	376	455	369	1,530	385	
Other HCV ⁽⁵⁾ – U.S.	25	35	37	22	119	24	30	34	27	115	24	
Other HCV ⁽⁵⁾ – Europe	44	8	12	10	74	8	16	7	9	40	18	
Other HCV ⁽⁵⁾ – Other Intl	4	2	3	5	14	2	3	2	3	10	4	
	73	45	52	37	207	34	49	44	39	166	45	
Total HCV – U.S.	258	327	224	209	1,018	199	263	283	260	1,005	232	
Total HCV – Europe	135	93	94	99	421	95	94	143	80	413	114	
Total HCV – Other Intl	117	129	111	85	442	105	91	98	98	392	99	
	510	549	429	393	1,881	399	448	524	439	1,810	445	

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽³⁾ Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by Gilead's separate subsidiary, Asegua Therapeutics LLC.

⁽⁴⁾ Amounts consist of sales of Eplclusa and the authorized generic version of Eplclusa sold by Gilead's separate subsidiary, Asegua Therapeutics LLC.

⁽⁵⁾ Includes Vosevi and Sovaldi.



PRODUCT SALES SUMMARY (continued)
(unaudited)

(in millions)	2021					2022					2023	
	Q1	Q2	Q3	Q4	FY21	Q1	Q2	Q3	Q4	FY22	Q1	
HBV/HDV												
Vemlidy – U.S.	77	86	103	118	384	80	97	129	123	429	87	
Vemlidy – Europe	8	8	9	9	34	9	9	9	8	35	9	
Vemlidy – Other Intl	96	106	96	98	396	111	89	90	89	379	103	
	181	200	208	225	814	200	195	228	220	842	199	
Viread – U.S.	4	3	1	3	11	—	3	2	2	6	(1)	
Viread – Europe	7	8	7	6	28	6	6	5	6	23	6	
Viread – Other Intl	20	17	18	17	72	17	15	15	14	62	14	
	31	28	26	26	111	23	24	22	22	91	19	
Other HBV/HDV ⁽⁶⁾ – U.S.	—	1	—	1	2	—	—	—	(1)	—	11	
Other HBV/HDV ⁽⁶⁾ – Europe	8	8	13	13	42	13	15	13	14	55	—	
	8	9	13	14	44	13	16	14	13	55	11	
Total HBV/HDV – U.S.	81	90	104	122	397	80	100	131	124	435	86	
Total HBV/HDV – Europe	23	24	29	28	104	28	30	28	28	112	26	
Total HBV/HDV – Other Intl	116	123	114	115	468	128	104	106	103	441	117	
	220	237	247	265	969	235	234	264	255	988	230	
Total Liver Disease – U.S.	339	417	328	331	1,415	279	363	413	384	1,440	318	
Total Liver Disease – Europe	158	117	123	127	525	123	124	170	108	525	140	
Total Liver Disease – Other Intl	233	252	225	200	910	233	195	204	202	833	217	
	730	786	676	658	2,850	635	682	788	694	2,798	675	
Veklury												
Veklury – U.S.	820	416	1,527	877	3,640	801	41	336	395	1,575	252	
Veklury – Europe	388	264	109	334	1,095	304	126	130	142	702	111	
Veklury – Other Intl	248	149	287	146	830	430	278	458	462	1,628	209	
	1,456	829	1,923	1,357	5,565	1,535	445	925	1,000	3,905	573	
Other												
AmBisome – U.S.	12	13	7	7	39	25	15	9	9	57	6	
AmBisome – Europe	66	69	67	72	274	66	63	63	66	258	60	
AmBisome – Other Intl	43	74	69	41	227	53	54	33	42	182	49	
	121	156	143	120	540	144	132	105	117	497	116	
Letairis – U.S.	54	57	46	49	206	43	49	43	60	196	32	
Other ⁽⁷⁾ – U.S.	38	37	34	27	136	26	37	28	44	135	30	
Other ⁽⁷⁾ – Europe	20	31	17	47	115	15	26	11	13	65	12	
Other ⁽⁷⁾ – Other Intl	8	10	5	7	30	9	13	13	18	53	9	
	66	78	56	81	281	50	76	52	75	253	51	
Total Other – U.S.	104	107	87	83	381	94	101	80	113	388	69	
Total Other – Europe	86	100	84	119	389	81	88	75	79	323	72	
Total Other – Other Intl	51	84	74	48	257	62	67	46	61	235	58	
	241	291	245	250	1,027	236	256	200	252	946	199	
Total product sales – U.S.	4,240	4,213	5,479	5,244	19,176	4,329	4,254	4,900	5,234	18,716	4,434	
Total product sales – Europe	1,275	1,147	997	1,259	4,678	1,174	1,042	1,064	1,061	4,342	1,053	
Total product sales – Other Intl	825	792	880	657	3,154	1,031	842	1,013	1,037	3,924	819	
	\$ 6,340	\$ 6,152	\$ 7,356	\$ 7,160	\$ 27,008	\$ 6,534	\$ 6,138	\$ 6,978	\$ 7,333	\$ 26,982	\$ 6,306	

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽⁶⁾ Includes Hepcludex and Hepsera.

⁽⁷⁾ Includes Cayston, Jyseleca, Ranexa and Zydelig.